Evidence map›Paper›PMID 41078387›Full record

ArticleNPJ dementia2025

Case of early onset Alzheimer's disease associated with a novel PSEN1 variant identified in Colombia.

Lina M Zapata-Restrepo, Bruce L Miller, Juan Rivas, Katherine Possin, Victor Valcour, Stefanie D Piña-Escudero, Agustin Ibañez, Kenneth S Kosik

Abstract readCase Reports
In one paragraph

Article in NPJ dementia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lina M Zapata-RestrepoFundacion Valle del Lili, Cali, Colombia.
Bruce L MillerGlobal Brain Health Institute - University of California San Francisco, San Francisco, CA USA.
Juan RivasFundacion Valle del Lili, Cali, Colombia.
Katherine PossinGlobal Brain Health Institute - University of California San Francisco, San Francisco, CA USA.
Victor ValcourGlobal Brain Health Institute - University of California San Francisco, San Francisco, CA USA.
Stefanie D Piña-EscuderoGlobal Brain Health Institute - University of California San Francisco, San Francisco, CA USA.
Agustin IbañezBrainLat Institute, Universidad Adolfo Ibáñez, Santiago, Chile.
Kenneth S KosikUniversity of California Santa Barbara, Santa Barbara, CA USA.

Funding

An automated machine learning approach to language changes in Alzheimer’s disease and frontotemporal dementia across Latino and English-speaking populationsR01AG075775 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARIA LUISA GORNO TEMPINI, Adolfo Martin Garcia · 2023 to 2026
$7.2M
Molecular Basis of the Tau Aggregation PathwayR01AG056058 · NIA · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI Songi Han, KENNETH Stephen KOSIK · 2017 to 2026
$6.4M
US-South American Initiative for Genetic-Neural-Behavioral Interactions in Human Neurodegenerative ResearchR01AG057234 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Claudia Duran-Aniotz, Agustin M. Ibanez · 2019 to 2026
$6.1M
Social epigenetics of Alzheimer's disease and related dementias in Latin American countriesR01AG082056 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI Michael Jay Corley · 2024 to 2026
$3.6M
Circadian Disturbance and Dementia in Latin AmericaR01AG083799 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Kun Hu, Agustin M. Ibanez · 2023 to 2026
$3.0M
NIA NIH HHS R01 AG056058NIA NIH HHS R01 AG057234NIA NIH HHS R01 AG075775NIA NIH HHS R01 AG082056NIA NIH HHS R01 AG083799NIDA NIH HHS 75N95022C00031
6 · The paper itself

Abstract

Early-onset Alzheimer's disease (EOAD) is a rare form of dementia that often progresses more quickly than late-onset cases, and is more commonly associated with autosomal dominant mutations. A 47-year-old male presented with progressive cognitive and behavioral decline, a family history of EOAD, and was later found to have a novel pathogenic PSEN1 variant (c.519 G > T, p.Leu173Phe). Initial evaluations, including neuroimaging and laboratory tests, were unremarkable. Neuropsychological testing later revealed memory impairment, executive dysfunction, and neuropsychiatric symptoms. These features, alongside the identified mutation, are consistent with phenotypic presentations of EOAD involving the third transmembrane domain of PSEN1. Pharmacological treatment with cholinesterase inhibitors and antipsychotics yielded limited benefit. Notably, the extended follow-up time, of more than 10 years from the early symptomatic stage, is a unique and valuable feature of this case study, providing rare longitudinal insight into the natural course of genetically confirmed EOAD.

Indexed as

Alzheimer's diseaseNeurological manifestations

Identifiers

PMID41078387
PMCPMC12513822

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.